Dipal Doshi, CEO at Entrada Therapeutics, Inc. (TRDA), sold 3,000 shares at $15.00 ($45K) on 2024-05-16, disclosed to the SEC on 2024-05-20.
Scheduled sale ($45k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.00 | 1,800 | $27K | 59.8% |
| 2 | $15.11 | 1,200 | $18K | 40.2% |
| Total | $15.04 avg | 3,000 | $45K | 100% |
| Filing → |
| TRDA | SELL | 2024-02-20 | $15K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |
| TRDA | SELL | 2023-12-22 | $15K | — | Filing → |